Freshfields and Clifford Chance Advise on UCB’s $680 Million Sale

ZipLaw Team

In Short: Belgian biopharma giant UCB is selling its portfolio of established products in China, including epilepsy drug Keppra and antihistamine Zyrtec, to Singapore's CBC Group and Abu Dhabi’s Mubadala Investment Co. for $680 million. This move allows UCB to focus on developing new medicines in China, especially in areas like immunology and neurology.

This post is for paying subscribers only

Subscribe

Already have an account? Log in

You might also like

EuroBox Deal Members Public

In Short: Segro PLC, a British logistics real estate giant, is set to acquire Tritax EuroBox in an all-share deal worth £552 million. This transaction offers Segro a broader European logistics portfolio while Tritax shareholders receive a premium on their shares.

ZipLaw Team
Deals

Freshfields advises in Ocean Deal Dive Members Public

In Short: Lloyd’s Register is buying a majority stake in Ocean Technologies Group (OTG) from private equity firm Oakley Capital for £50 million. The acquisition will boost Lloyd’s Register’s maritime technology and services portfolio, with a particular focus on training for sustainable maritime practices.

ZipLaw Team
Freshfields Bruckhaus Deringer

Featured Posts

Hogan Lovells - Application Insider

Booming Cases

Application Insider - Latham & Watkins

Authors →

Ludo Lugnani

ZipLaw Team